The abstract is read at the publisher; the summary is JClub's.
In adults with metabolic dysfunction-associated steatohepatitis and F2–F4c fibrosis, zalfermin 30 mg plus semaglutide 2·4 mg did not significantly improve NASH CRN fibrosis by week 52 versus placebo (24% vs 16%).
- Why it matters: The trial addresses whether once-weekly dual incretin-based therapy can achieve fibrosis improvement without worsening metabolic dysfunction-associated steatohepatitis in patients with clinically significant fibrosis, including compensated cirrhosis (F4c).
- What they did: In a double-blind, dose-ranging randomized trial across 187 sites, 698 participants received weekly zalfermin plus semaglutide, single-agent regimens, cagrilintide plus semaglutide, or placebo for 52 weeks; the primary endpoint required ≥1 fibrosis-stage improvement with no worsening.
- The result: Semaglutide 2·4 mg alone showed a nominally significant benefit versus placebo (30% vs 16%; EDP 14·05, 95% CI 1·88 to 26·23; p=0·024), while the combination was not significant (EDP 7·98, 95% CI -3·82 to 19·79; p=0·19); adverse events were mostly mild to moderate.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.